Obsidian Therapeutics (NASDAQ:OBX) Research Coverage Started at Piper Sandler

Piper Sandler began coverage on shares of Obsidian Therapeutics (NASDAQ:OBX) in a research report sent to investors on Wednesday morning, Marketbeat.com reports. The firm issued an overweight rating and a $42.00 price objective on the stock.

Obsidian Therapeutics Stock Performance

NASDAQ:OBX opened at $27.50 on Wednesday. Obsidian Therapeutics has a twelve month low of $23.00 and a twelve month high of $49.97.

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.